Safety and efficacy results of cizutamig, an investigational B-cell maturation antigen x cluster of differentiation 3 (BCMA×CD3) T-cell engager: Interim results from a Phase 1b open-label, ...
Beam Therapeutics is reaffirmed as a long-term buy, with significant upside expected around 2028–2029 as BEAM-302 advances.
A clinical trial called "PARTNERS" is evaluating Infusion of MBP134, a monoclonal antibody cocktail, Infusion of Remdesivir, and Infusion of both, as a treatment for Ebola BDBV infection against ...
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's ...
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results